Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamate ionotropic receptor delta type subunit 1 (GRID1, also known as GluD1) is a member of the ionotropic glutamate receptor family, which plays a key role in the organization and function of synapses in the central nervous system[1][2][6]. Unlike classical ionotropic glutamate receptors, GRID1 does not bind glutamate as a primary ligand; instead, it forms trans-synaptic adhesion complexes, regulating the activity of NMDA and AMPA receptors and influencing both excitatory and inhibitory synaptic plasticity[1][2]. GRID1 is involved in diverse biological processes critical for brain connectivity and synaptic transmission, and genetic variants or dysfunctions in GRID1 are implicated in neurodevelopmental and neuropsychiatric disorders, including Rett syndrome and spinocerebellar ataxia 18[1][2][6]. Despite being structurally homologous to other glutamate receptors and able to form cation channels, current evidence suggests its primary roles are in synaptic signaling modulation and neuronal network organization rather than direct chemical neurotransmission. No approved drugs selectively target GRID1, and its therapeutic potential remains an area of active research[1][2].
Not established for drugs; molecular modulation includes forming trans-synaptic adhesion complexes with neurexins and cerebellins, regulation of NMDA, AMPA, and GABA receptor activity[1][2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate ionotropic receptor delta type subunit 1 (GRID1).